Found: 5
Select item for more details and to access through your institution.
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42400-5
- By:
- Publication type:
- Article
Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis.
- Published in:
- Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-023-01413-1
- By:
- Publication type:
- Article
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors.
- Published in:
- Journal of Pathology: Clinical Research, 2024, v. 10, n. 2, p. 1, doi. 10.1002/cjp2.354
- By:
- Publication type:
- Article
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
- Published in:
- Journal of Pathology: Clinical Research, 2022, v. 8, n. 4, p. 371, doi. 10.1002/cjp2.271
- By:
- Publication type:
- Article
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 251, doi. 10.1007/s00262-021-02981-w
- By:
- Publication type:
- Article